- Home
- OKUR vs MRSN Comparison
OKUR vs MRSN Comparison
Compare OKUR & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- MRSN
- Stock Information
- Founded
- OKUR 2011
- MRSN 2001
- Country
- OKUR United States
- MRSN United States
- Employees
- OKUR N/A
- MRSN N/A
- Industry
- OKUR
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- OKUR
- MRSN Health Care
- Exchange
- OKUR NYSE
- MRSN Nasdaq
- Market Cap
- OKUR 34.9M
- MRSN 40.7M
- IPO Year
- OKUR N/A
- MRSN 2017
- Fundamental
- Price
- OKUR $2.52
- MRSN $0.34
- Analyst Decision
- OKUR Strong Buy
- MRSN Strong Buy
- Analyst Count
- OKUR 4
- MRSN 5
- Target Price
- OKUR $32.25
- MRSN $5.75
- AVG Volume (30 Days)
- OKUR 69.8K
- MRSN 3.0M
- Earning Date
- OKUR 08-14-2025
- MRSN 08-12-2025
- Dividend Yield
- OKUR N/A
- MRSN N/A
- EPS Growth
- OKUR N/A
- MRSN N/A
- EPS
- OKUR N/A
- MRSN N/A
- Revenue
- OKUR N/A
- MRSN $34,006,000.00
- Revenue This Year
- OKUR N/A
- MRSN N/A
- Revenue Next Year
- OKUR N/A
- MRSN $1.30
- P/E Ratio
- OKUR N/A
- MRSN N/A
- Revenue Growth
- OKUR N/A
- MRSN N/A
- 52 Week Low
- OKUR $1.70
- MRSN $0.26
- 52 Week High
- OKUR $20.00
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- MRSN 51.10
- Support Level
- OKUR N/A
- MRSN $0.27
- Resistance Level
- OKUR N/A
- MRSN $0.36
- Average True Range (ATR)
- OKUR 0.00
- MRSN 0.03
- MACD
- OKUR 0.00
- MRSN 0.01
- Stochastic Oscillator
- OKUR 0.00
- MRSN 61.58
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.